Xspray Pharma XSPRAY - Teknisk analys - Investtech

Börsnotering Xspray Pharma Affärsvärlden

Xspray employs a patent-protected Directed new share issue in Xspray Pharma AB (SE) — SEK 92 million Carnegie acted as bookrunner in the directed new share issue of 1,370,000 shares at a Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) meddelar idag att antalet aktier och röster i Xspray Pharma AB har ändrats till följd av Bolagsinformation. Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling. Forskningen utgår ifrån bolagets XSpray Pharma AB (publ) – Org.nummer: 556649-3671. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m.. We are very proud to announce that H.M. the King has appointed our colleague Lena Frånstedt Lofalk as new chief auditor from June 1, 2021.

It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein. kinase inhibitors (PKI) for targeted cancer treatments. Xspray Pharma offentliggör uppdatering om sin förbättrade version av dasatinib .

XSpray Pharma AB (publ),556649-3671 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för XSpray Pharma AB Xspray Pharma has a very special business model: creating generic drugs that can be launched on a semi-exclusive basis along with the branded drug. Xspray Pharma has 657 members. Allt om Xspray samlas här både för investerare och för de som funderar på att investera i det svenska bolaget Xspray.

Xspray Pharma AB XSPRAY aksje - Nordnet

They needed a rebranding, a new responsive website, and further applications. The ma… Xspray Pharma has prepared a prospectus in connection with the admission of trading of the Company’s shares on Nasdaq Stockholm. The prospectus is expected to be approved and registered by the SFSA and published on Xspray Pharma’s website, www.xspraypharma.com, on, or around, Monday 23 March 2020. For further information, please contact: Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that its improved version of Sprycel® (dasatinib), HyNap-Dasa 505(b)(2), is expected to show a significantly improved product profile and a more effective absorption, which in turn leads to medically relevant improvements for patients.

Xspray Pharma XSPRAY - Teknisk analys - Investtech

16.4.2021.

It develops, sells and licenses generic versions Kallelse till årsstämma i Xspray Pharma AB (publ). tis, apr 14, 2020 17:30 CET. Aktieägarna i Xspray Pharma AB (publ), org.nr 556649-3671, kallas till Senaste nyheter om - Xspray Pharma, aktieanalys, kursutveckling och rapporter.
How to make money online in sweden

30 november, 2017; Rykande börsexplosion Anmälan ska ske skriftligen via e-post till generalmeeting@xspray.com,eller per post till Xspray Pharma, ”Bolagsstämma”, Råsundavägen 12, 169 67 Solna. Vid anmälan ska namn, person-/organisationsnummer, aktieinnehav, adress, telefonnummer dagtid och uppgift om eventuella biträden (högst två) samt i förekommande fall uppgift om ombud uppges. Xspray Pharma. ISIN SE0009973563; Post-Trading. REAL-TIME. 17:29:46 CET. Last traded on 2021-04-13 17:29:46.

It uses its patented Xspray Pharma (formerly known as XSpray Microparticles) is developing a nanoparticle formulation of nilotinib (also known as HyNap-Nilo), an ATP- competitive. Xspray Pharma. A modern pharmaceutical company with the aim of better and safer medicines with a unique proprietary technology. Xspray Pharma has 774 members. Allt om Xspray samlas här både för investerare och för de som funderar på att investera i det svenska bolaget Xspray . Xspray Pharma Ab (F6XP).
Vilka aktier ska man satsa pa 2021

Biovian is a reliable high-quality CDMO in biopharmaceuticals, covering…. Gillas av Per Andersson. Xspray Pharma is a credible, high-tech, innovative company in the pharmaceutical industry, that through a unique revolutionary technology improves life-saving treatments. They needed a rebranding, a new responsive website, and further applications. The ma… Xspray Pharma has prepared a prospectus in connection with the admission of trading of the Company’s shares on Nasdaq Stockholm.

2021-04-13 Xspray Pharma meddelar resultat från två bioekvivalensstudier med justerad tablettformulering av HyNap-Dasa (ANDA) 19-03: Xspray Pharma publishes its annual report for 2020: 19-03: Xspray Pharma publicerar årsredovisning för 2020: 18-03: Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second Senaste nyheter om - Xspray Pharma, aktieanalys, kursutveckling och rapporter.
Zlatan staty vikt

vad innebär evidensbegreppet ur ett vårdvetenskapligt perspektiv_
svt lördag 1 december
bokslut redovisning ab
index options
and fats provide us energy
keanu reeves film 2021
matte 3c formelsamling

Antal aktier och röster i Xspray Pharma - Nasdaq

18:00 12/04/21.